NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-03-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatientmetastaticsquamous celltherapy
  Phrases that lowered it: the efficacyinvestigatorplatinumjudgedpatients
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 52795 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 6327 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 88.6% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer NCT02817113 · started 2016 · scored riskier than 38% of active trials terminated
• Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck NCT01412229 · started 2012 · scored riskier than 99% of active trials completed
• Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCT00971932 · started 2009 · scored riskier than 55% of active trials completed
• Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN NCT02124707 · started 2014 · scored riskier than 98% of active trials completed
• A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer NCT01057589 · started 2010 · scored riskier than 69% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.